arsenic trioxide has been researched along with Neuroblastoma in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Feng, C; Li, C; Li, P; Li, Y; Peng, X; Wang, Z; Wu, P; Xiong, X | 1 |
| Chen, Y; Feng, C; Li, C; Li, P; Li, Y; Peng, X; Weng, W; Wu, Y; Xiong, X; Zhou, D; Zhu, Y | 1 |
| Lei, PC; Li, GL; Liu, HJ | 1 |
| Feng, C; He, Y; Li, C; Li, J; Li, Y; Liang, X; Liao, N; Lin, Y; Liu, A; Peng, X; Tian, X; Wang, S; Wu, P; Xiong, X; Yang, Z | 1 |
| Afzal, M; Ahmad, F; Ali, A; Anis, E; Firdaus, F; Hossain, MM; Zafeer, MF | 1 |
| Chuchu, F; Huang, K; Li, Y; Qi, K; Weng, W; Xiong, X; Zhang, C | 1 |
| Andersson, LC; Bironaite, D; Venalis, A; Westberg, JA | 1 |
| Delaune, A; Dubus, I; Falluel-Morel, A; Goullé, JP; Petit, A; Vannier, JP; Vasse, M | 1 |
| Alimoghaddam, K; Ghaffari, SH; Ghanizadeh-Vesali, S; Ghavamzadeh, A; Hassani, S; Hosseini, E; Rostami, M; Yousefi, M; Zekri, A | 1 |
| Carrasquillo, JA; Cheung, NK; Kramer, K; Kushner, BH; Larson, SM; Modak, S; Pandit-Taskar, N; Zanzonico, P | 1 |
| Fang, J; Guo, H; Li, Y; Liu, L; Qi, K; Xiong, X; Zhang, C | 1 |
| Büsselberg, D; Florea, AM; Günes, DA; Splettstoesser, F | 1 |
| Karlsson, J; Påhlman, S; Pörn-Ares, I; Øra, I | 1 |
| Edsjö, A; Karlsson, J; Påhlman, S; Pettersson, HM | 1 |
| Cheung, WM; Chu, PW; Kwong, YL | 1 |
| Ahn, HS; Jang, JJ; Jung, HS; Kim, CJ; Kim, HS; Lee, MJ; Ryu, KH; Seoh, JY; Shin, HY | 1 |
| Beckman, S; Karlsson, J; Larsson, C; Påhlman, S; Pettersson, HM; Pietras, A | 1 |
| Karlsson, J; Påhlman, S; Pettersson, HM; Pietras, A; Øra, I | 1 |
| Büsselberg, D; Florea, AM | 1 |
| Akao, Y; Akiyama, K; Nakagawa, Y | 1 |
| Akao, Y; Nakagawa, Y; Yamada, H | 1 |
| Bondesson, L; Garwicz, S; Jönsson, C; Ljungberg, J; Ora, I; Pâhlman, S; Pörn-Ares, I | 1 |
2 review(s) available for arsenic trioxide and Neuroblastoma
| Article | Year |
|---|---|
Arsenic trioxide and neuroblastoma cytotoxicity.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Brain Neoplasms; Cell Death; Cell Differentiation; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Neuroblastoma; Oxides | 2007 |
Arsenic-induced apoptosis in malignant cells in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Down-Regulation; Glutathione; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, B-Cell; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Neuroblastoma; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2000 |
2 trial(s) available for arsenic trioxide and Neuroblastoma
| Article | Year |
|---|---|
Excellent Early Outcomes of Combined Chemotherapy With Arsenic Trioxide for Stage 4/M Neuroblastoma in Children: A Multicenter Nonrandomized Controlled Trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Cardiotoxicity; Child; Child, Preschool; Female; Humans; Infant; Male; Neoplasm Staging; Neuroblastoma; Survival Rate; Treatment Outcome | 2021 |
Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Topics: 3-Iodobenzylguanidine; Adolescent; Adrenal Gland Neoplasms; Adult; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Male; Neuroblastoma; Oxides; Paraganglioma; Pheochromocytoma; Radiation-Sensitizing Agents; Radiopharmaceuticals; Survival Analysis; Treatment Outcome | 2016 |
18 other study(ies) available for arsenic trioxide and Neuroblastoma
| Article | Year |
|---|---|
Arsenic trioxide induces the differentiation of retinoic acid-resistant neuroblastoma cells via upregulation of HoxC9.
Topics: Apoptosis; Arsenic Trioxide; Cell Differentiation; Cell Line, Tumor; Homeodomain Proteins; Humans; Neuroblastoma; Proteomics; Tretinoin; Up-Regulation | 2022 |
Arsenic trioxide increases apoptosis of SK-N-BE (2) cells partially by inducing GPX4-mediated ferroptosis.
Topics: Apoptosis; Arsenic Trioxide; Child; Ferroptosis; Humans; Iron; Neuroblastoma; Proteomics | 2022 |
[PDCD4 enhances the inhibitory effect of As(2)O(3) on the growth and NF-κB signaling pathway in neuroblastoma cells].
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Cell Differentiation; Cell Survival; Humans; Neuroblastoma; NF-kappa B; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; Signal Transduction | 2019 |
Evaluation of phyto-medicinal efficacy of thymoquinone against Arsenic induced mitochondrial dysfunction and cytotoxicity in SH-SY5Y cells.
Topics: Antioxidants; Apoptosis; Arsenic Trioxide; Benzoquinones; Cell Line, Tumor; Cell Survival; Humans; Mitochondria; Neuroblastoma; Neurons; Neuroprotective Agents; Nigella sativa; Poly (ADP-Ribose) Polymerase-1; Reactive Oxygen Species | 2019 |
Pre-application of arsenic trioxide may potentiate cytotoxic effects of vinorelbine/docetaxel on neuroblastoma SK-N-SH cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Cell Line, Tumor; Docetaxel; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Mitosis; Neuroblastoma; Vinorelbine | 2019 |
A variety of mild stresses upregulate stanniocalcin-1 (STC-1) and induce mitohormesis in neural crest-derived cells.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Calcium; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Flow Cytometry; Glycoproteins; Hormesis; Humans; Membrane Potential, Mitochondrial; Mitochondria; Neuroblastoma; Oxides; Phorbol Esters; Reactive Oxygen Species; Starvation; Stress, Physiological; Time Factors; Up-Regulation | 2013 |
Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Intranuclear Inclusion Bodies; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; N-Myc Proto-Oncogene Protein; Neurites; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Oxides; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Suppressor Proteins | 2013 |
Differential sensitivity of p44/p42-MAPK- and PI3K/Akt-targeted neuroblastoma subtypes to arsenic trioxide.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Line, Tumor; Cell Proliferation; DNA Primers; Enzyme Activation; Flow Cytometry; Humans; Neuroblastoma; Oxides; Protein Kinases; Real-Time Polymerase Chain Reaction | 2013 |
Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; G2 Phase Cell Cycle Checkpoints; Humans; Neuroblastoma; Oxides | 2016 |
Co-application of arsenic trioxide (As2O3) and cisplatin (CDDP) on human SY-5Y neuroblastoma cells has differential effects on the intracellular calcium concentration ([Ca2+]i) and cytotoxicity.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Cell Line, Tumor; Cisplatin; Cytotoxins; Drug Therapy, Combination; Humans; Intracellular Fluid; Neuroblastoma; Oxides | 2009 |
Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Blotting, Western; Calpain; Carboplatin; Caspase 3; Caspases; Cell Line, Tumor; Cytochromes c; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Mutation; Neuroblastoma; Oxides; Proto-Oncogene Proteins c-bcl-2; Time Factors; Tumor Suppressor Protein p53; Vincristine | 2004 |
Multidrug-resistant neuroblastoma cells are responsive to arsenic trioxide at both normoxia and hypoxia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 3; Caspases; Cell Death; Cell Hypoxia; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Neuroblastoma; Oxides; Reference Values; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2005 |
Effects of arsenic trioxide on the cellular proliferation, apoptosis and differentiation of human neuroblastoma cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Growth Inhibitors; Humans; Indoles; Neuroblastoma; Neurofilament Proteins; Neurons; Oxides; Protein Kinase C; Receptor, trkA; Receptor, trkB; Tyrosine 3-Monooxygenase; Up-Regulation | 2007 |
Arsenic trioxide concentration determines the fate of Ewing's sarcoma family tumors and neuroblastoma cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Enzyme Activation; Enzyme Inhibitors; Fibroblast Growth Factor 2; Flavonoids; Humans; In Vitro Techniques; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 1; Mitogen-Activated Protein Kinase 1; Neuroblastoma; Neurons; Oxides; Phenotype; Sarcoma, Ewing | 2006 |
Arsenic trioxide-induced neuroblastoma cell death is accompanied by proteolytic activation of nuclear Bax.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Cell Death; Cell Line, Tumor; Cell Nucleus; Enzyme Activation; Humans; Neuroblastoma; Oxides; Peptide Hydrolases | 2007 |
Arsenic trioxide in environmentally and clinically relevant concentrations interacts with calcium homeostasis and induces cell type specific cell death in tumor and non-tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Calcium Signaling; Cell Line, Tumor; Cell Survival; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Homeostasis; Humans; Kidney; Micronuclei, Chromosome-Defective; Microscopy, Confocal; Neuroblastoma; Oxides; Trypan Blue | 2008 |
Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Enzyme Activation; Glutathione; Humans; Neuroblastoma; Oxides; Tumor Cells, Cultured | 1999 |
Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro.
Topics: Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase Inhibitors; Caspases; Cell Differentiation; Cell Division; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Neoplasm Transplantation; Neuroblastoma; Oxides; RNA, Messenger; Tetrazolium Salts; Thiazoles; Transplantation, Heterologous; Tretinoin; Tumor Cells, Cultured | 2000 |